Gilead Sciences, Inc. (Durham, NC)
4 University Place
4611 University Drive
Durham
North Carolina
27707
United States
Tel: 919-493-5980
Fax: 919-493-5925
Website: http://www.gilead.com/
Email: public_affairs@gilead.com
About Gilead Sciences, Inc. (Durham, NC)
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need.The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.
Key Contacts: John C. Martin, PhD, Chairman and Chief Executive Officer John F. Milligan, PhD, President and Chief Operating Officer Norbert W. Bischofberger, PhD, Executive Vice President, Research and Development and Chief Scientific Officer Kevin Young, Executive Vice President, Commercial Operations
Kristen Metza, Senior Vice President, Human Resources Susan Hubbard, Vice President, Investor Relations Amy Flood, Senior Director, Public Affairs
Last Updated: 07-15-2008
33 articles about Gilead Sciences, Inc. (Durham, NC)
-
Gilead Sciences (Foster City, CA) To Acquire Myogen For $2.5 Billion
10/2/2006
-
India's JB Chemicals & Pharmaceuticals Limited To Make And Sell Gilead Sciences (Foster City, CA) Drug
9/22/2006
-
Gilead Sciences, Inc. (Durham, NC) To Present At The Bear Stearns 19th Annual Healthcare Conference On Tuesday, September 12th; Webcast Available Through b>Gilead Corporate Website
9/11/2006
-
Gilead Sciences (Foster City, CA) Exercises Option To Acquire Corus Pharma, Inc. For $365 Million
8/3/2006
-
Gilead Sciences (Foster City, CA) Agrees To Exercise Its Option To Acquire Corus Pharma, Inc. For $365 Million
7/20/2006
-
Gilead Sciences (Foster City, CA) To Release Second Quarter 2006 Financial Results On Thursday, July 20, 2006
7/17/2006
-
Gilead Sciences (Foster City, CA) And The Institute Of Organic Chemistry And Biochemistry Establish New Academic Research Centre In Prague
7/13/2006
-
FDA Approves Gilead Sciences (Foster City, CA) And Bristol-Myers Squibb Company's ATRIPLA(TM), The First Once-Daily Single Tablet Regimen For Adults With HIV-1 Infection
7/13/2006
-
All-In-One Pill For HIV
7/10/2006
-
Gilead Sciences (Foster City, CA) To Acquire Degussa's Raylo Chemicals Inc. For Approximately 115.2 Million Euros
6/6/2006
-
Gilead Sciences (Foster City, CA) Announces Dismissal Of Securities Litigation
5/16/2006
-
Diatos S.A. Announces Acquisition Of Specialty Cancer Product DaunoXome(R) From Gilead Sciences (Foster City, CA)
5/11/2006
-
Gilead Sciences (Foster City, CA) To Present At Two Upcoming Investor Conferences
5/1/2006
-
Bristol-Myers Squibb Company And Gilead Sciences (Foster City, CA) Submit New Drug Application To U.S. FDA For A Once-Daily Single Tablet Regimen Of Sustiva(R) And Truvada(R) For HIV Treatment
4/27/2006
-
Gilead Sciences (Foster City, CA) Closes Sale Of $1.3 Billion Convertible Senior Notes
4/25/2006
-
Gilead Sciences (Foster City, CA) Prices $1.2 Billion Convertible Senior Notes
4/20/2006
-
Gilead Sciences (Foster City, CA) Announces First Quarter 2006 Financial Results
4/19/2006
-
Gilead Sciences (Foster City, CA) To Release First Quarter 2006 Financial Results On Tuesday, April 18, 2006
4/17/2006
-
The Day In Review: Pfizer Inc. Buys Drug, Settles Patent
4/13/2006
-
Gilead Sciences (Foster City, CA) Invests $25 Million In Corus Pharma, Inc.
4/13/2006